A study of potential skin atrophy following topical application of weak corticosteroids.
A double-blind, half-side comparative dermal atrophy study of fluocortin butylester 0.75% clobetasone butyrate 0.05%, hydrocortisone acetate 1% and placebo creams was carried out in 29 healthy human male volunteers. Skin thickness was measured by a modified radiographic technique before and after an 8-week application period of the test preparations. Significant skin thinning occurred in 3 of the 10 subjects treated with clobetasone butyrate and atrophy of marginal significance in 1 of the 29 subjects treated with fluocortin butylester. The results suggest that, compared with other fluorinated topical steroids, fluocortin butylester 0.75% is unlikely to produce significant dermal atrophy when used in the short and medium term.
D000287:Administration, Topical; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001284:Atrophy / Q000139:chemically induced; D002990:Clobetasol / Q000009:adverse effects / Q000031:analogs & derivatives; D004311:Double-Blind Method; D005448:Fluocortolone / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012867:Skin / Q000473:pathology*
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D010919:Placebos; C021650:hydrocortisone acetate; D005448:Fluocortolone; C011824:fluocortin butyl ester; C010893:clobetasone butyrate; D002990:Clobetasol; D006854:Hydrocortisone